AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 56 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,489 | -62.4% | 3,306 | -75.8% | 0.00% | – |
Q1 2023 | $3,961 | -89.1% | 13,656 | -83.0% | 0.00% | – |
Q4 2022 | $36,199 | -58.9% | 80,461 | -52.2% | 0.00% | – |
Q3 2022 | $88,000 | -40.5% | 168,258 | -42.7% | 0.00% | – |
Q2 2022 | $148,000 | -64.6% | 293,834 | +61.7% | 0.00% | – |
Q1 2022 | $418,000 | -55.2% | 181,701 | -7.4% | 0.00% | – |
Q4 2021 | $932,000 | -39.6% | 196,218 | +1.0% | 0.00% | – |
Q3 2021 | $1,544,000 | +13.4% | 194,225 | -0.7% | 0.00% | – |
Q2 2021 | $1,362,000 | +54.8% | 195,535 | +76.0% | 0.00% | – |
Q1 2021 | $880,000 | -12.7% | 111,090 | -13.3% | 0.00% | – |
Q4 2020 | $1,008,000 | +304.8% | 128,090 | +265.0% | 0.00% | – |
Q3 2020 | $249,000 | +6.0% | 35,091 | +37.8% | 0.00% | – |
Q2 2020 | $235,000 | +1368.8% | 25,467 | +636.7% | 0.00% | – |
Q1 2020 | $16,000 | -94.2% | 3,457 | -90.4% | 0.00% | – |
Q4 2019 | $276,000 | +338.1% | 36,127 | +344.8% | 0.00% | – |
Q3 2019 | $63,000 | -81.3% | 8,122 | -83.5% | 0.00% | – |
Q2 2019 | $337,000 | +374.6% | 49,319 | +460.2% | 0.00% | – |
Q1 2019 | $71,000 | -64.9% | 8,804 | -67.4% | 0.00% | – |
Q4 2018 | $202,000 | -29.1% | 26,983 | -9.5% | 0.00% | – |
Q3 2018 | $285,000 | -33.3% | 29,818 | -26.0% | 0.00% | – |
Q2 2018 | $427,000 | +484.9% | 40,308 | +442.9% | 0.00% | – |
Q1 2018 | $73,000 | +356.2% | 7,424 | +144.9% | 0.00% | – |
Q4 2017 | $16,000 | +6.7% | 3,032 | 0.0% | 0.00% | – |
Q3 2017 | $15,000 | +36.4% | 3,032 | +9.7% | 0.00% | – |
Q2 2017 | $11,000 | -72.5% | 2,765 | -49.4% | 0.00% | – |
Q1 2017 | $40,000 | +66.7% | 5,464 | 0.0% | 0.00% | – |
Q4 2016 | $24,000 | -4.0% | 5,464 | +44.2% | 0.00% | – |
Q3 2016 | $25,000 | – | 3,790 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |